



Pluristem Announces Scientific and Investment Conferences for April 2013

HAIFA, Israel April 10, 2013 -- Pluristem Therapeutics Inc. (NASDAQCM: [PSTI](#)) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today the Company is scheduled to participate in several scientific and investment conferences in April 2013. To schedule a meeting with us upon availability, contact us at info@pluristem.com.

[Bizportal Biomed 2013 Conference](#)

On April 10th in Tel-Aviv, Zami Aberman, Chairman and CEO, will participate in a panel discussion entitled "Tel-Aviv New York, Gazing to the American Market and the Exit Dream" at the Bizportal Biomed 2013 Conference.

[Regenerative Medicine Investor Day](#)

On April 17th in New York City, Mr. Aberman will present at the Regenerative Medicine Investor Day hosted by the [Alliance for Regenerative Medicine](#). The conference provides institutional, strategic and venture investors a unique opportunity to gain insight into the top regenerative medicine and advanced therapies companies.

[Israstem, The Annual Israeli Meeting of Translational Research on Stem Cells, Cell Therapy and Regenerative Medicine in Industry and Academia](#)

On April 22nd – 23rd, Dr. Ohad Karnieli, VP Development and Dr. Racheli Ofir, Intellectual Property & Senior Scientist, will chair a session entitled "Tools for Research and Development" and give a presentation entitled "A Harmonized Approach in the Regulation of PLX-PAD" respectively.

[BIO-International 2013 Convention](#)

From April 22nd – 25th, Mr. Aberman and Dr. William Prather, Sr. VP of Corporate Development, will participate in the BIO-International 2013 Convention in Chicago, Illinois. This popular biotechnology meeting is well attended by specialty and large pharmaceutical companies from all over the world.

[19th ISCT Annual Conference](#)

On April 24th, Dr. Ohad Karnieli, VP Development, will give a presentation entitled "Challenges and Possible Solutions to Overcome the Gap in Critical Supply Chain Issues

of New and Evolving Cutting Edge Technologies of Cell Therapy” at the Annual International Society for Cell Therapy Conference in Auckland, New Zealand.

[International Advanced Course on Regenerative Medicine Manufacturing](#)

From April 28th - May 4th, Lior Raviv, Team Lead Process Development, will lecture at the course on Regenerative Medicine Manufacturing in Tavira-Algarve, Portugal.

[Needham Healthcare Conference](#)

From April 30th - May 1st, Dr. Prather will attend the 12th Annual Needham Healthcare Conference held in New York City.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.

Pluristem has a strong patent and patent applications portfolio, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect

the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

Contact:

Pluristem Therapeutics Inc.:

William Prather R.Ph., M.D. Sr. VP Corporate Development

1-303-883-4954

William.PratherMD@pluristem.com

Daya Lettvin

Investor & Media Relations Director

+972-54-674-5580

daya@pluristem.com